References
- Brand W, Boersma MG, Bik H, et al. (2010). Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples. Drug Metab Dispos 38:617–25.
- Chiou CS, Lin JW, Kao PF, et al. (2008). Effects of hesperidin on cyclic strain-induced endothelin-1 release in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol 35:938–43.
- Cho J. (2006). Antioxidant and neuroprotective effects of hesperidin and its aglycone hesperetin. Arch Pharm Res 29:699–706.
- Fabre N, Rustan I, Hoffmann E, Quetin-Leclercq J. (2001). Determination of flavone, flavonol, and flavanone aglycones by negative ion liquid chromatography electrospray ion trap mass spectrometry. J Am Soc Mass Spectrom 12:707–15.
- Garg A, Garg S, Zaneveld L, Singla A. (2001). Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 15:655–69.
- Gaur V, Kumar A. (2010). Hesperidin pre-treatment attenuates NO-mediated cerebral ischemic reperfusion injury and memory dysfunction. Pharmacol Rep 62:635–48.
- Kanaze FI, Bounartzi MI, Georgarakis M, Niopas I. (2007). Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutr 61:472–7.
- Kim HJ, Jeon SM, Lee MK, et al. (2010). Comparison of hesperetin and its metabolites for cholesterol-lowering and antioxidative efficacy in hypercholesterolemic hamsters. J Med Food 13:808–14.
- Londoño-Londoño J, Lima VR, Jaramillo C, Creczynski-Pasa T. (2010). Hesperidin and hesperetin membrane interaction: understanding the role of 7-O-glycoside moiety in flavonoids. Arch Biochem Biophys 499:6–16.
- Matsumoto H, Ikoma Y, Sugiura M, et al. (2004). Identification and quantification of the conjugated metabolites derived from orally administered hesperidin in rat plasma. J Agric Food Chem 52:6653–9.
- Nielsen IL, Chee WS, Poulsen L, et al. (2006). Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. J Nutr 136:404–8.
- Nielsen SE, Breinholt V, Justesen U, et al. (1998). In vitro biotransformation of flavonoids by rat liver microsomes. Xenobiotica 28:389–401.
- Oztanir MN, Ciftci O, Cetin A, Aladag MA. (2014). Hesperidin attenuates oxidative and neuronal damage caused by global cerebral ischemia/reperfusion in a C57BL/J6 mouse model. Neurol Sci 35:1393–9.
- Roohbakhsh A, Parhiz H, Soltani F, et al. (2014). Neuropharmacological properties and pharmacokinetics of the citrus flavonoids hesperidin and hesperetin—a mini-review. Life Sci 113:1–6.
- Silberberg M, Gil-Izquierdo A, Combaret L, et al. (2006). Flavanone metabolism in healthy and tumor-bearing rats. Biomed Pharmacother 60:529–35.
- Wang F, Cao GS, Li Y, et al. (2018). Characterization of forsythoside A metabolites in rats by a combination of UHPLC-LTQ-Orbitrap mass spectrometer with multiple data processing techniques. Biomed Chromatogr 32:e4164.
- Yamada M, Tanabe F, Arai N, et al. (2006). Bioavailability of glucosyl hesperidin in rats. Biosci Biotechnol Biochem 70:1386–94.
- Yogeeta SK, Hanumantra RB, Gnanapragasam A, et al. (2006). Attenuation of abnormalities in the lipid metabolism during experimental myocardial infarction induced by isoproterenol in rats: beneficial effect of ferulic acid and ascorbic acid. Basic Clin Pharmacol Toxicol 98:467–72.